Literature DB >> 11779326

The management of severe infectious mononucleosis tonsillitis and upper airway obstruction.

S C Chan1, P J Dawes.   

Abstract

Acute tonsillectomy has been advocated for severe infectious mononucleosis (IM) pharyngotonsillitis with upper airway obstruction (UAO) and not responding to corticosteroids. This paper reviews and rationalizes our management. A five-year chart review was carried out with a follow-up telephone survey. There were 36 admissions. Nine had UAO of whom 89 per cent (eight of nine patients) had a tonsillectomy. The diagnosis of UAO was not standardized. Twenty-seven patients did not have UAO and only a small proportion of these patients, 16 per cent (four of 25) went on to have an elective tonsillectomy. Corticosteroids made no significant difference to the tonsillectomy rate. UAO appears to identify patients with more severe disease who are likely to suffer recurrent tonsillitis. Acute tonsillectomy is an appropriate treatment option for this subgroup. The diagnosis of significant IM UAO is not defined and a schema is proposed. Recurrent tonsillitis is an uncommon sequela of severe IM pharyngotonsillitis without UAO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11779326     DOI: 10.1258/0022215011909792

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

Review 1.  Tonsillitis and sore throat in children.

Authors:  Klaus Stelter
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2014-12-01

2.  An Uncommon Cause of Severe Upper Airway Obstruction in a Toddler.

Authors:  Carlos Castillo; Carston Ruffo
Journal:  Glob Pediatr Health       Date:  2017-10-27

Review 3.  Epstein-Barr virus and its association with disease - a review of relevance to general practice.

Authors:  Anders Fugl; Christen Lykkegaard Andersen
Journal:  BMC Fam Pract       Date:  2019-05-14       Impact factor: 2.497

Review 4.  Infections of the airway.

Authors:  Ian A Jenkins; Michael Saunders
Journal:  Paediatr Anaesth       Date:  2009-07       Impact factor: 2.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.